The Double Marker Test is a crucial prenatal screening performed during the first trimester of pregnancy, typically between the 11th and 14th weeks. It is a blood test that measures two key substances—Free Beta-hCG and PAPP-A (Pregnancy-Associated Plasma Protein A)—to assess the risk of chromosomal abnormalities such as Down syndrome (Trisomy 21) and Edwards syndrome (Trisomy 18) in the developing fetus. While the Double Marker Test does not confirm these conditions, it helps categorize pregnancies into low-risk or high-risk, guiding further diagnostic decisions. Combined with an ultrasound for nuchal translucency (NT scan), the test provides a clearer picture of the baby's health early on. Recommended for women of all ages, especially those over 35 or with a family history of genetic conditions, the Double Marker Test plays a key role in ensuring early detection and better pregnancy management.